ERSP Finds True Earth Health Products Can Support Certain Claims for ‘Plexaderm,’ Recommends Marketer Modify Certain Claims

New York, NY – Sept. 8, 2017 – The Electronic Retailing Self-Regulation Program (ERSP) has determined that True Earth Health Products can support certain claims for Plexaderm, but recommended the marketer modify or discontinue other claims.

ERSP is an investigative unit of the advertising industry’s system of self-regulation and is administered by the Council of Better Business Bureaus. The marketer’s advertising came to the attention of ERSP pursuant to its ongoing monitoring program.

ERSP reviewed online and broadcast advertising claims for Plexaderm and identified several claims for review, including:

  • “Plexaderm uses silicates to lift wrinkles and tighten bags, creating a smoother, healthier, more youthful looking complexion.”
  • “Once you apply Plexaderm cream, the mix of skin tightening crystals and moisturizing agent absorb quickly onto the skin to help visibly smooth stubborn wrinkles and reduce under eye puffiness.”
  • “Plexaderm Rapid Reduction Cream smooths fine lines and firms skin, redefines facial contours, improves skin density, refines skin texture for face and neck lines and minimizes pores.”
  • “Plexaderm visibly reduces under eye puffiness, fine lines and wrinkles in minutes”
  • “50% Off Limited Time Offer”

During the initial stages of ERSP’s inquiry, the marketer informed ERSP that the testimonials at issue had been discontinued.

As support for the performance claims at issue, the marketer provided ERSP with clinical study and survey data.

Based upon the collective evidence in the test record, ERSP concluded that the marketer provided a reasonable basis for claims that “Plexaderm visibly reduces under eye puffiness, fine lines and wrinkles in minutes” and “Once you apply Plexaderm cream, the mix of skin tightening crystals and moisturizing agent absorb quickly onto the skin to help visibly smooth stubborn wrinkles and reduce under eye puffiness.”

However, ERSP recommended that the marketer modify the claim that “Plexaderm Rapid Reduction Cream smooths fine lines and firms skin, redefines facial contours, improves skin density, refines skin texture for face and neck lines and minimizes pores” to limit its performance efficacy claims to the specific benefits that were supported by its clinical testing; more specifically, the reduction of fine lines and wrinkles and minimization of pores around the eyes.

ERSP determined that the marketer’s online establishment claims (i.e., “95% of the group agreed that the wrinkles around their eyes looked less noticeable;” “95% of the group agreed that the bags and puffiness under their eyes looked less noticeable;” “92.5% of the group agreed that the dark circles around and under their eyes looked less noticeable;” etc.) were supported by reliable survey data that was accurately presented for consumers in the advertising. Conversely, with respect to the one television advertisement that discussed the results of the test questionnaire, ERSP was not similarly persuaded that data was accurately presented to consumers. ERSP recommended that the marketer modify its presentation of the clinical test results and the survey responses in its broadcast advertising.

Finally, ERSP concluded that the “limited time offer” was available for essentially ten consecutive months and therefore was not a “limited time” price reduction. Accordingly, ERSP recommended that the marketer discontinue its use of presenting the price point of Plexaderm as a “50% Off Limited Time Offer.”

The company, in its marketer’s statement, said, “…we will take ERSP’s recommendations into account when developing future advertising. As an advocate of self-regulation, we support ERSP and appreciate its thoughtful and diligent review of this matter.”

 

Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.

 

 

 

 

Latest Decisions

Decision

National Advertising Division Recommends Blueprint Test Preparation Discontinue Certain MCAT Score Improvement Claims

New York, NY – April 22, 2024 – The National Advertising Division recommended Blueprint Test Preparation discontinue certain express and implied claims made in connection with its four MCAT preparation courses, including claims that Blueprint students raise their MCAT scores by 15 or 13 points on average.

Read the Decision Summary
Decision

National Advertising Division Recommends The Princeton Review Discontinue Point Increase Claims for MCAT Test Preparation Services

New York, NY – April 18, 2024 – In a Fast-Track SWIFT challenge, the National Advertising Division recommended that The Princeton Review (TPR) discontinue claims that its students “Score a 515+ on the MCAT or add 15 points depending on your starting score. Guaranteed or your money back.”

Read the Decision Summary
Decision

Direct Selling Self-Regulatory Council Recommends Trades of Hope Discontinue Salesforce Member Earnings Claims

McLean, VA – April 17, 2024 – The Direct Selling Self-Regulatory Council (DSSRC) recommended that Trades of Hope discontinue certain earnings claims made by salesforce members on Facebook and YouTube. 

Read the Decision Summary
Decision

National Advertising Division Recommends Lily of the Desert Nutraceuticals Discontinue “100% Pure Avocado Oil” Claim for Tropical Plantation Avocado Oil

New York, NY – April 15, 2024 – The National Advertising Division recommended that Lily of the Desert Nutraceuticals discontinue the claim “100% Pure Avocado Oil” for its Tropical Plantation Avocado Oil and avoid conveying the unsupported message that the product is 100% pure avocado...

Read the Decision Summary